OpenPV Signal Explorer
FAERS disproportionality dashboard
Reaction

Bile Duct Obstruction reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,899 reports · 52 co-occurring drugs

As of the last recalculation, Bile Duct Obstruction appears in 1,899 FAERS reports alongside 52 co-occurring drug terms. The strongest observed disproportionality signal is OCTREOTIDE ACETATE (PRR 22.9).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
DrugCo-reportsPRRROR
Octreotide Acetate6222.922.9
Regorafenib2019.119.1
Trifluridine And Tipiracil1616.516.5
Drospirenone And Ethinyl Estradiol5413.813.8
Lapatinib1913.513.6
Gemcitabine Hydrochloride6313.413.4
Sitagliptin And Metformin Hydrochloride2613.413.4
Pyrazinamide1112.912.9
Gemcitabine4211.911.9
Sitagliptin7111.211.2
Erlotinib Hydrochloride1210.610.6
Ursosiol179.79.7
Ursodiol199.69.7
Pancrelipase339.59.5
Sennosides 8.6 Mg Tablets189.59.5
Senna189.49.4
Cholestyramine109.19.1
Erlotinib89.19.1
Isoniazid138.88.9
Terbinafine Hydrochloride78.78.7
Leucovorin Calcium158.78.7
Senna Leaf188.68.6
Sorafenib168.58.5
Meperidine Hydrochloride78.48.4
Capecitabine678.38.3
Exenatide388.18.1
Cetuximab227.87.8
Panitumumab117.77.7
Rifampicin77.67.6
Sennosides207.47.4
Nicotine Polacrilex Mini107.37.3
Nicotine Polarilex107.37.3
Everolimus327.07.0
Tramadol Hydrochloride236.86.8
Naproxen Sodium Tablet, Coated86.56.5
Naproxen Sodium, Coated Tablets86.56.5
Naproxen Sodium 220Mg86.56.5
Oxaliplatin426.36.3
Prochlorperazine Maleate56.06.0
Ado-Trastuzumab Emtansine45.25.2
Irinotecan Hydrochloride65.15.1
Sunitinib Malate174.84.8
Imatinib Mesylate124.74.7
Entecavir54.74.7
Dornase Alfa84.54.5
Pazopanib Hydrochloride104.14.1
Ipilimumab153.83.8
Nivolumab313.63.6
Liraglutide153.33.3
Glecaprevir And Pibrentasvir33.03.0
Olaparib52.62.6
Orlistat52.12.1

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.